Introduction The rapid evolution of Phase 1 clinical trials in Brazil presents both a remarkable opportunity and a daunting challenge for sponsors. The average approval timeline has now shrunk to just...
<h2 id="introduction">Introduction</h2> <p>The rapid evolution of Phase 1 clinical trials in Brazil presents both a remarkable opportunity and a daunting challenge for sponsors. The average approval timeline has now shrunk to just 90 days, allowing early-stage companies to fast-track their market entry. However, this speed necessitates strict compliance with ANVISA regulations and ICH-GCP standards.</p> <p>What strategies can sponsors adopt to leverage local partnerships and innovative recruitment methods, ensuring they meet regulatory demands while boosting patient engagement and operational efficiency?</p> <h2 id="understand-brazils-regulatory-framework-for-phase-1-trials">Understand Brazil's Regulatory Framework for Phase 1 Trials</h2> <p>Navigating the <a href="https://bioaccessla.com/br/services">phase 1 clinical trial Brazil</a> landscape requires a keen understanding of its <a…